NewGenIvf Group (NIVF) to Post Quarterly Earnings on Wednesday

NewGenIvf Group (NASDAQ:NIVF) is expected to be issuing its resultson Wednesday, September 2nd. Analysts expect NewGenIvf Group to announce earnings of $6.06 per share and revenue of $20.10 million for the quarter.

NewGenIvf Group Stock Performance

NIVF opened at $0.42 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. The company’s 50 day moving average is $1.05 and its 200 day moving average is $3.93. NewGenIvf Group has a 12-month low of $0.40 and a 12-month high of $513.00.

Shares of NewGenIvf Group are going to reverse split before the market opens on Tuesday, September 1st. The 1-3 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

Analysts Set New Price Targets

NIVF has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NewGenIvf Group presently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.